medigraphic.com
ISSN 0016-3813 (Print)

2011, Number 2

<< Back Next >>

Gac Med Mex 2011; 147 (2)

Citomegalovirus reactivation in critical ill intensive care patients

Carrillo ER

Language: Spanish
References: 34
Page: 159-162
PDF size: 80.83 Kb.


ABSTRACT

Cytomegalovirus (CMV) is a β herpesvirus and a significant human pathogen. After primary infection establishes life long latency. In immunocompetent individuals cell-mediated host immune responses prevent the development of overt CMV disease. It has increasingly come to be recognized that critically ill patients are at risk for CMV reactivation from the latency. The risk factors associated to CMV reactivation in the critically ill are infection, sepsis, trauma, transfusions, major surgery, prolonged mechanical ventilation, steroids and vasopressors. In the pathogenesis are involved immunodysfunction and imbalance in immunomodulatory mediators principally tumor necrosis factor (TNF) and nuclear factor κB (NF-κB). Several studies have shown an association between CMV reactivation in immunocompetent critically ill patients and poor clinical outcomes. Further studies are warranted to identify subsets of patients who are at risk of developing CMV reactivation and to determine the role of antiviral agents on clinically outcomes in critically ill patients.


REFERENCES

  1. Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol. 2006;87:1763-9.

  2. Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol. 2008;41:180-5.

  3. Michelson S. Human cytomegalovirus escape from immune detection. Intervirology. 1999;42:301-7.

  4. Cebulla CM, Miller DM, Sedmak DD. Viral inhibition of interferon signal transduction. Intervirology. 1999;42:325-30.

  5. Beisser PS, Vink C, Van Dam JG, Grauls SJ, Vanherle SJ, Bruggeman CA. The R33 G protein coupled receptor gene of rat cytomegalovirus plays an essential role in the pathogenesis of viral infection. J Virol. 1998;72:2352-63.

  6. Duncombe AS, Meager A, Prentice HG, et al. Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus. Blood. 1990;76:1046-53.

  7. Haagmans BL, Stals FS, Van der Meide PH, Bruggeman CA, Horzinek MC, Schijns VE. Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus. J Virol. 1994;68:2297-304.

  8. Hengel H, Lucin P, Jonjic S, Ruppert T, Koszinowski UH. Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J Virol. 1994;68:289-97.

  9. Fennie EH, Lie Ys, Low Ma, Gribling P, Anderson KP. Reduced mortality in murine cytomegalovirus infected mice following prophylactic murine interferon-gamma treatment. Antiviral Res. 1988;10:27-39.

  10. Söderberg-Nauclér C, Fish KN, Nelson JA. Interferon-a and tumour necrosis factor-specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest. 1997;100:1-10.

  11. Humbert M, Roux-Lombard P, Cerrina J, et al. Soluble TNF receptors (TNF-sR55 and TNF-sR75) in lung allograft recipients displaying cytomegalovirus pneumonitis. Am J Resp Crit Care Med. 1994;149:1681-5.

  12. Fietze E, Prosch S, Reinke P, et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation. 1994;58:675-80.

  13. Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G. High incidence of active cytomegalovirus infections among septic patients. Clin Infect Dis. 1998;26:1076-82.

  14. Heininger A, Vogel U, Aepinus C, Hamprecht K. Disseminated fatal human cytomegalovirus disease after severe multiple trauma. Crit Care Med. 2000;28:563-6.

  15. Döcke WD, Prösch S, Fietze E, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet. 1994;343:268-9.

  16. Cook C, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak D. Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1b triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol. 2006;80:9151-8.

  17. Cook C, Zhang B, McGuinness B, Lahm M, Sedmak D, Ferguson R. Intraabdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Inect Dis. 2002;185:1395-400.

  18. Domart Y, Trouillet JL, Fagon JY. Incidence and morbidity of cytomegaloviral infection in patients with mediastinitis following cardiac surgery. Chest. 1990;97:18-22.

  19. Stevenson GW, Hall SC, Rudnick S. The effect of anesthetic agents on the human immune response. Anesthesiology. 1990;72:542-52.

  20. Faist E, Schinkel C, Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg. 1996;20:454-9.

  21. Stephan F, Meharzi D, Ricci S. Evaluation by polymerase chain reaction of cytomegalovirus reactivation in intensive care patients under mechanical ventilation. Intensive Care Med. 1996;22:1244-9.

  22. Heininger A, Jahn G, Engel C, Notheisen T, Unerti K, Hamprecht K. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Cri Care Med. 2001;29:541-7.

  23. Kusne S, Grossi P, Irish W, et al. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation. 1999;68:1125-31.

  24. Bein G, Bitsch A, Hoyer J, Kirchner H. The detection of human cytomegalovirus immediate early antigen in peripheral blood leukocytes. J Immunol Methods. 1991;137:175-80.

  25. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-7.

  26. Drew WL. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. Curr Opin Infect Dis. 2007; 20(4):408-11.

  27. Desachy A, Ranger-Rogez S, Francois B, et al. Reactivation of human herpesvirus type 6 in multiple organ failure syndrome. Clin Infect Dis. 2001;32:197-203.

  28. Von Muller L, Klemm A, Weiss M, et al. Active cytomegalovirus infection in patients with septic shock. Emerg Infect Dis. 2006;12:1517-22.

  29. Jaber S, Chanques G, Borry J, et al. Cytomegalovirus Infection in Critically III Patients. Chest. 2005;127:233-41.

  30. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivatiom in critically ill immunocompetent patients. JAMA. 2008;300(4):413-22.

  31. Chiche L, Forel JM, Roch A, et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med. 2009;37:1850-7.

  32. Osawa R, Singh N. Cytomegalovirus in critically ill patients: a systematic reviw. Critical Care. 2009;13R:1-10.

  33. Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmnosuppressed patients in the intensive care unit. Crit Care Med. 2009;37:2350-8.

  34. Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009;13:410-20.




2020     |     www.medigraphic.com